Combining BSO with Chemotherapy to Treat Tumors
Author Information
Author(s): D.W. Siemann, K.L. Beyers
Primary Institution: University of Rochester Cancer Center
Hypothesis
Can the thiol depleting agent buthionine sulfoximine (BSO) enhance the effectiveness of alkylating chemotherapy agents in treating tumors?
Conclusion
The study found that combining BSO with melphalan significantly increased its antitumor efficacy without enhancing bone marrow toxicity.
Supporting Evidence
- BSO treatment led to a significant reduction in tumor GSH levels.
- The combination of BSO and melphalan resulted in a 1.4-fold increase in tumor cell killing.
- Multiple dosing of BSO did not yield further therapeutic benefits compared to a single dose.
- Maintaining BSO in drinking water resulted in a significant increase in melphalan efficacy without increasing bone marrow toxicity.
Takeaway
Researchers tested a drug called BSO to see if it could make cancer treatments work better. They found that it helped one specific treatment, melphalan, kill more cancer cells without hurting healthy cells too much.
Methodology
Mice with KHT sarcomas were treated with BSO and various alkylating agents, and tumor response was assessed through clonogenic cell survival assays.
Potential Biases
Potential bias in the selection of treatment protocols and assessment methods.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
8-12 week old female C3H/HeJ mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website